Canakinumab is under clinical development by Novartis and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase II drugs for Chronic Myelomonocytic Leukemia (CMML) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Canakinumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Canakinumab overview
Canakinumab (Ilaris / Lasprona / Vyncro) is a fully human monoclonal antibody. It is formulated as powder for solution and solution for subcutaneous route of administration. Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including Familial Cold Autoinflammatory Syndrome (FCAS), tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), Familial Mediterranean Fever (FMF), Muckle-Wells Syndrome (MWS), pancreatic cancer and symptomatic anemia. Ilaris is also approved for systemic onset juvenile idiopathic arthritis in patients aged 2 years and older. Ilaris is also indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks, and for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Canakinumab is indicated for emergency use in the treatment of COVID-19.
Canakinumab (Ilaris) is under development for the treatment of myelodysplastic syndrome, adult onset still's disease (AOSD), renal cell carcinoma, metastatic non-squamous non-small cell lung cancer (adjuvant and first line therapy), metastatic melanoma, alcoholic hepatitis, pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome, knee osteoarthritis, anemia, pancreatic cancer, pancreatic ductal adenocarcinoma. It is also administered through intra-articular route.
It was also under development for the treatment of mild cognitive impairment due to Alzheimer's disease, pulmonary sarcoidosis, arterial structure, pain associated with sickle cell anemia patients, function in intermittent claudication patients, gouty arthritis (in the US), abdominal aortic aneurysms, choroidal neovascularization, rheumatoid arthritis, type 1 diabetes, type 2 diabetes, chronic obstructive pulmonary disease (COPD), feratoconjunctivitis sicca (dry eye), secondary prevention of cardiovascular events, Kawasaki disease, urticaria vasculitis, polymyalgia rheumatica, non-small cell lung cancer (second line and third line therapy), COVID-19-induced pneumonia, cytokine release syndrome, metastatic triple negative breast cancer and squamous non-small cell lung cancer (first line therapy), Behcet disease.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Canakinumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
